In the large subset of MLLr ALL patients where PROM1/CD133 is co-expressed with CD19, CD133/CD19 dual AND gate targeting could be a promising targeted therapeutic approach in difficult-to-treat infants, children, and adults. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.